

# Walker Chandiook & Co LLP

Walker Chandiook & Co LLP  
(Formerly Walker, Chandiook & Co)  
7th Floor, Block III, White House  
Kundan Bagh, Begumpet  
Hyderabad 500016  
India

T +91 40 6630 8200  
F +91 40 6630 8230

## Review Report

### To the Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Neuland Laboratories Limited ("the Company") for the quarter ended 30 June 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*Walker Chandiook & Co LLP*  
For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

*Sanjay Kumar Jain*  
per Sanjay Kumar Jain  
Partner

Membership No. 207660

Place: Hyderabad

Date: 14 August 2015



**NEULAND LABORATORIES LIMITED**


Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 34

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2015**

**PART - I**

Amount in ₹ Lacs

Sl. No.	Particulars	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 31.03.2015 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Year Ended 31.03.2015 (Audited)
1	<b>Income from Operations</b>				
	(a) Net Sales / Income from Operations	11,515.03	12,358.72	9,984.79	44,506.38
	(b) Other Operating Income	748.18	938.12	282.66	1,963.97
	<b>Total Income from Operations (Net)</b>	<b>12,263.21</b>	<b>13,296.84</b>	<b>10,267.45</b>	<b>46,470.35</b>
2	<b>Expenses</b>				
	(a) Consumption of Raw Materials	6,700.39	6,537.73	6,368.23	26,641.78
	(b) Changes in inventories of finished goods and work in process	(375.35)	677.81	(922.35)	(2,242.89)
	(c) Employee Benefit Expense	1,308.82	1,376.03	1,054.44	4,896.61
	(d) Depreciation	380.20	362.28	389.90	1,531.98
	(e) Manufacturing Expenses	1,444.13	1,265.74	1,241.51	5,563.22
	(f) Other Expenses	1,183.40	1,488.40	1,165.17	5,419.95
	<b>Total Expenses</b>	<b>10,641.59</b>	<b>11,707.99</b>	<b>9,296.90</b>	<b>41,810.65</b>
3	<b>Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>1,621.62</b>	<b>1,588.85</b>	<b>970.55</b>	<b>4,659.70</b>
4	Other Income	161.63	129.40	73.44	522.87
5	<b>Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)</b>	<b>1,783.25</b>	<b>1,718.25</b>	<b>1,043.99</b>	<b>5,182.57</b>
6	Finance Costs	654.10	860.37	567.82	2,734.86
7	<b>Profit from Ordinary Activities after Finance Costs but before Exceptional Items (5-6)</b>	<b>1,129.15</b>	<b>857.88</b>	<b>476.17</b>	<b>2,447.71</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit from Ordinary Activities before Tax (7-8)</b>	<b>1,129.15</b>	<b>857.88</b>	<b>476.17</b>	<b>2,447.71</b>
10	Tax Expense				
	(a) Current tax	475.68	302.87	103.90	671.38
	(b) Deferred Tax	(76.59)	(73.80)	173.83	198.20
	(c) MAT Credit entitlement	-	60.12	(103.90)	-
11	<b>Net Profit from Ordinary Activities after Tax (9-10)</b>	<b>730.06</b>	<b>568.69</b>	<b>302.34</b>	<b>1,578.13</b>
12	Extraordinary Items	-	-	-	-
13	<b>Net Profit for the period (11-12)</b>	<b>730.06</b>	<b>568.69</b>	<b>302.34</b>	<b>1,578.13</b>
14	Paid-up Equity Share Capital (Face Value ₹10 per share)	895.39	895.39	772.63	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				15,010.27
16	Earnings per Share (EPS) (in ₹)				
	(a) Basic	8.22	6.40	3.65	18.47
	(b) Diluted	8.22	6.40	3.65	18.47



**PART - II**

Sl. No.	Particulars	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 31.03.2015 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Year Ended 31.03.2015 (Audited)
<b>A</b>	<b>PARTICULARS OF SHARE HOLDING</b>				
1	Public Shareholding				
	(a) Number of Shares	42,87,627	42,87,627	38,22,899	42,87,627
	(b) Percentage of Shareholding	48.27%	48.27%	49.94%	48.27%
2	Promoters and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	4.35%	4.35%	5.22%	4.35%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.25%	2.25%	2.61%	2.25%
	(b) Non-encumbered				
	-Number of Shares	43,95,627	43,95,627	36,32,779	43,95,627
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	95.65%	95.65%	94.78%	95.65%
	-Percentage of Shares (as a % of the total share capital of the Company)	49.48%	49.48%	47.45%	49.48%

**B INVESTOR COMPLIANTS**

Particulars	Quarter Ended 30.06.2015
Pending at the beginning of the quarter	1
Received during the quarter	4
Disposed off during the quarter	5
Remaining unresolved at the end of the quarter	0

**NOTES:**

- The above audited financial results have been reviewed by the Audit Committee at their meeting held on August 13, 2015, and approved and taken on record at the Board of Directors meeting held on August 14, 2015.
- EPS for the quarters are not annualized. EPS for the quarter ended June 30, 2014 has been recomputed to adjusted for the bonus element of rights issue in accordance with the provisions of AS 20 - Earnings per Share.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board  
For Neuland Laboratories Limited




Dr. D.R. Rao  
Chairman & Managing Director  
(DIN 00107737)

Place: Hyderabad  
Date: August 14, 2015